[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Inari Medical\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":161},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,69,91,111,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100493189","defiance-rct-of-clottriever-system-versus-anticoagulation-in-deep-vein-thrombosis-100493189",false,"NCT05701917","DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","DEFIANCE - ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis","DEFIANCE","Inclusion Criteria\n\n* Age ≥ 18 years\n* Proximal lower extremity unilateral DVT involving at least the common femoral, external iliac, or common iliac veins, alone or in combination\n* Symptom onset within 12 weeks of enrollment in the study\n* Significant symptoms, as defined by a Villalta score \\> 9\n* Willing and able to provide informed consent\n\nExclusion Criteria\n\n* Bilateral iliofemoral DVT\n* Prior venous stent in the target venous segment\n* IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n* IVC filter in place at the time of enrollment\n* Limb-threatening circulatory compromise (e.g., phlegmasia)\n* Clot in transit including IVC thrombus presenting as extension of \\>2cm into the IVC from the CIV\n* Symptomatic PE with right heart strain where the physician judges that a DVT intervention is inappropriate at this time.\n* Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement\n* Severe allergy, hypersensitivity to, or thrombocytopenia from heparin\n* Severe allergy to iodinated contrast agents that cannot be mitigated\n* Hemoglobin \\\u003C 8.0 g\u002FdL, INR \\> 1.7 before warfarin was started, or platelets \\\u003C 50,000\u002Fµl which cannot be corrected prior to enrollment\n* Severe renal impairment (estimated GFR \\\u003C 30 ml\u002Fmin) in patients who are not yet on dialysis\n* Inability to provide therapeutic anticoagulation per Investigator discretion\n* Uncontrolled severe hypertension on repeated readings (systolic \\> 180mmHg or diastolic \\> 105mmHg)\n* Recently (\\\u003C 30 days) had DVT interventional procedure\n* Subject is participating in another study that may interfere with this study\n* Life expectancy \\\u003C 6 months or chronic non-ambulatory status\n* Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n* Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., contraindication to use of ClotTriever per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)\n* Subject has previously completed or withdrawn from this study\n* Patient unwilling or unable to conduct the follow up visits per protocol","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.",[27,28,29],"Venous Thromboembolism","Deep Venous Thrombosis","Post-Thrombotic Syndrome",[27,28,29,31,32],"Anticoagulation","Percutaneous Mechanical Thrombectomy","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2023-01-06",{"date":41,"type":21},"2027-01-15",{"name":43,"class":44},"Inari Medical","INDUSTRY",64,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100546423","revcore-for-in-stent-thrombosis-100546423","NCT06394739","RevCore for In Stent Thrombosis","RevCore for In Stent Thrombosis (REVIT)","REVIT","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients with stent age \\> 6 weeks\n3. Location of thrombosed stents in proximal lower extremity deep vein segments including at least common femoral, external iliac, or common iliac vein\n4. RevCore Thrombectomy Catheter must enter vasculature\n5. Willing and able to provide informed consent\n\nExclusion Criteria:\n\n1. Exposed stents with broken struts, significantly deformed struts, struts protruding into the vessel\n2. Stents not wall apposed\n3. Stents compressed to \\\u003C10mm\n4. Bilateral in-stent thrombosis\n5. Congenital anatomic anomalies of the iliac veins\n6. Allergy, hypersensitivity, or thrombocytopenia from heparin or iodinated contrast agents, except for mild to moderate contrast allergies for which pretreatment can be used\n7. Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n8. Chronic non-ambulatory status\n9. Known hypercoagulable states (e.g. antiphospholipid syndrome) that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n10. Inability to secure venous access\n11. Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n12. Current participation in another investigational drug or device treatment study",{"count":55,"type":21},100,"OBSERVATIONAL","The purpose of this research is to collect information about how the RevCore Thrombectomy Catheter works to treat stent blockages.",[59],"In-stent Thrombosis","2026-06-11",{"date":62,"type":37},"2026-06-15",{"date":64,"type":37},"2024-09-09",{"date":66,"type":21},"2028-04",{"name":43,"class":44},16,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100520388","the-peerless-ii-study-100520388","NCT06055920","The PEERLESS II Study","PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism","Inclusion Criteria:\n\n1. Age at enrollment ≥ 18 years\n2. Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality\n3. RV dysfunction, as defined as one or more of the following: RV\u002FLV ratio ≥ 0.9 or RV dilation or hypokinesis\n4. At least two additional risk factors, identified by at least one measure in two separate categories noted below:\n\n   a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate \\> 100 bpm b. Biomarker: i. Elevated\\* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated\\* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol\u002FL \\* Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation \\\u003C 90% on room air ii. Supplemental O2 requirement ≥ 4 L\u002Fmin iii. Respiratory rate ≥ 20 breaths\u002Fmin iv. mMRC score \\> 0\n5. Symptom onset within 14 days of confirmed PE diagnosis\n6. Willing and able to provide informed consent\n\nExclusion Criteria:\n\n1. Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin\n2. Presentation with hemodynamic instability\\* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following\n\n   1. Cardiac arrest OR\n   2. Systolic BP \\\u003C 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR\n   3. Systolic BP \\\u003C 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis \\* Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.\n3. Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated\n4. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental\u002Fsubsegmental distribution, predominately chronic clot)\n5. End stage medical condition with life expectancy \\\u003C 3 months, as determined by the Investigator\n6. Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study\n7. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1\n8. If objective testing was performed\\*, estimated RV systolic pressure \\> 70 mmHg on standard of care echocardiography \\* If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion\n9. Administration of advanced therapies (thrombolytic bolus, thrombolytic drip\u002Finfusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment\n10. Ventricular arrhythmias refractory to treatment at the time of enrollment\n11. Known to have heparin-induced thrombocytopenia (HIT)\n12. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling\n13. Subject is currently pregnant\n14. Subject has previously completed or withdrawn from this study",{"count":77,"type":21},1200,[24],"This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.",[81],"Pulmonary Embolism","2026-06-09",{"date":84,"type":37},"2026-06-10",{"date":86,"type":37},"2023-11-17",{"date":88,"type":21},"2026-07",{"name":43,"class":44},83,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":99,"studyType":56,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100562236","inari-vision-registry-100562236","NCT06600542","Inari VISION Registry","Inclusion Criteria:\n\n1. Willing and able to provide informed consent per institution and geographical requirements\n2. Has received treatment with an eligible Inari Medical device. NOTE: If patients are consented prior to their procedure and the procedure does not take place, the patient will be considered a screen failure.\n3. Currently within enrollment window relative to their procedure\n4. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Is or will be inaccessible for registry follow-up\n2. Meets exclusion criteria required by local requirements\n3. Current or planned participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this registry\n4. Is pregnant or breastfeeding at the time of enrollment",{"count":98,"type":21},1000,"180 Days","This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products.",[81],"2026-06-03",{"date":104,"type":37},"2026-06-04",{"date":106,"type":37},"2025-03-07",{"date":108,"type":21},"2029-12-31",{"name":43,"class":44},10,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100561320","the-persevere-study-100561320","NCT06588634","The PERSEVERE Study","Inclusion Criteria:\n\n1. Age at enrollment ≥18 years\n2. Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery\n3. High-risk class of acute PE\n4. RV dysfunction, as defined RV\u002FLV ratio ≥1.0\n5. Willing and able to provide informed consent, or if unable, through a Legal Authorized Representative, with permitting research without prior consent as a third option (for Europe and UK sites only), provided compliance with IRB\u002FEC approvals and adherence to regulatory, ethical and national standards\n\nExclusion Criteria:\n\n1. Prolonged cardiac arrest with loss of consciousness associated with neurological deficit.\n2. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention\n3. Known pre-existing CTEPH, or CT signs of chronic PE that may point to pre-existing CTEPH\n4. Recent stroke (\\\u003C14 days)\n5. Recent cranial or spinal surgery (\\\u003C14 days)\n6. Life-threatening active bleeding or hemorrhage into a critical area\n7. Known intracranial tumor\n8. End-stage medical condition with life expectancy \\\u003C3 months (irrespective of the severity of acute PE), as determined by the Investigator\n9. Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated\n10. Inability to anticoagulate the patient, or known to have heparin-induced thrombocytopenia (HIT)\n11. Current participation in another drug or device study that may interfere with the conduct of this trial\n12. Ventricular arrhythmias refractory to treatment at the time of enrollment\n13. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments), including a contraindication to use of FlowTriever System per local approved labeling\n14. Subject is part of a vulnerable population (e.g., currently pregnant, breastfeeding or incarcerated) per local definitions\n15. Subject was previously enrolled in this study\n16. Subject has received prior thrombolytic (systemic or catheter-directed) therapy for any reason or thrombectomy (surgical or catheter-based) therapy for index PE, within 30 days prior to randomization",{"count":118,"type":21},200,[24],"Randomized Controlled Trial of High-Risk Pulmonary Embolism Comparing FlowTriever System vs. Standard of Care",[81,122],"Pulmonary Thromboembolism",[124,81,125,126,127,31],"PE","FlowTriever","CDT","Catheter Directed Thrombolysis","2026-06-02",{"date":104,"type":37},{"date":131,"type":37},"2024-12-16",{"date":133,"type":21},"2028-02",{"name":43,"class":44},26,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100603390","the-artixascend-study-100603390","NCT07135895","The ArtixASCEND Study","The Artix All-in-one Solution for Complete thrombEctomy With eNDovascular Approach","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Acute symptom duration ≤ 14 days\n* Lower limb arterial occlusion below inguinal ligament\n* Target lesion in native vessel\n* Target vessel size between 3 mm and 8 mm by visual estimation\n* Rutherford category I, IIa, or IIb\n* Informed consent is obtained from either patient or legally authorized representative (LAR) per Institutional Review Board\u002FEthics Committee requirements\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 6 months\n* Prior major amputation in the target limb\n* Prior minor amputation in the target limb that is not completely healed or cannot bear weight\n* Non-thrombotic occlusion secondary to dissection, vasculitis, or target vessel trauma\n* Treatment of the index event in the target vessel with any other endovascular thrombectomy\u002Faspiration or open surgical method prior to Artix procedure\n* Part of a vulnerable population (e.g., currently pregnant, breastfeeding or incarcerated) per local definitions\n* Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated\n* Unable to tolerate antiplatelet therapy\n* Inability to anticoagulate the patient with heparin, enoxaparin or other parenteral antithrombin, or known to have uncorrected bleeding disorders (e.g., gastro-intestinal ulcer, menorrhagia, liver failure, heparin-induced thrombocytopenia (HIT))\n* Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., contraindication to use of Artix per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)\n* Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study",{"count":144,"type":21},250,[24],"This study is a post-market, prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions.",[148],"Acute Lower Limb Arterial Occlusion",[150,151,152],"Acute Limb Ischemia","Lower limb arterial occlusion","Artix Thrombectomy System","2026-06-01",{"date":128,"type":37},{"date":156,"type":37},"2026-01-07",{"date":158,"type":21},"2029-10-01",{"name":43,"class":44},14,""]